Notably, targeting of Rac1 by depletion of specific Rac-guanine nucleotide exchange factors (Rac-GEFs) fails to hinder the tumor growth in the presence of KRAS mutations, limiting its clinical use for advanced tumors [54]. Here, KRAS is linked to neoplasm.